The healthy immune system extinguishes infections while preserving the body’s integrity and preventing inflammatory reactions against harmless components through mechanisms of immune tolerance.
Autoimmune diseases and allergies are conditions where immune tolerance fails.
Most current treatments suppress immune cells irrespective of the components they recognize (their specific antigens), thereby compromising the defense against infection and immune surveillance. A key advantage of antigen-specific immune tolerance induction (such as the Topas approach) is the potential to specifically target pathogenic immune reactions while sparing desired immunity.
Liver sinusoidal endothelial cells (LSECs) are constantly exposed to bloodborne antigens (mostly gut-derived) that they take up and present effectively to naïve T cells, a central type of immune cell.
Given the need to induce and preserve tolerance to innocuous non-replicating antigens, LSECs are poised to promote immune tolerance. Through their ability to activate a key anti-inflammatory mediator (latent TGF-β) on their surface, LSECs support the induction of anti-inflammatory regulatory T cells (Tregs), a critically important type of immune cell for maintaining immune tolerance.
Topas’ technology platform harnesses the natural mechanisms of the liver to promote immune tolerance to blood borne antigens. Small peptide-loaded nanoparticles, Topas Particle Conjugates (TPCs), mimic such blood borne antigens and are taken up by LSECs. LSECs present these antigens to T cells under anti-inflammatory conditions conducive to the induction of tolerogenic Tregs and/or by other mechanisms. The therapeutic generation of Tregs serves to re-instate healthy immune balance (homeostasis) and can provide a cure for diseases characterized by undesirable or dysregulated inflammatory immune reactions.